Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 4/2013

01.04.2013 | Interventional Cardiology (S Rao, Section Editor)

Combining PCI and CABG: the Role of Hybrid Revascularization

verfasst von: Kelly D. Green, Donald R. Lynch Jr., Tyffany P. Chen, David Zhao

Erschienen in: Current Cardiology Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Hybrid coronary revascularization combines the benefits of both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in the treatment of multivessel coronary artery disease (CAD) by combining the benefits of the LIMA-to-LAD graft and drug eluting stent (DES) to non-LAD regions. Through this approach, a patient receives the long-term benefit of the LIMA graft and avoids the morbidity of a full sternotomy and saphenous vein grafts. Available data related to outcomes following hybrid revascularization is limited to small studies. In this review we seek to provide an overview of hybrid revascularization in the era of modern drug eluting stent technology, discuss appropriate patient selection, and comment on future trial design. Additionally, we review the recent literature pertaining to the hybrid approach.
Literatur
1.
Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation. Lancet. 1996;347(9003):757–8.PubMedCrossRef
2.
Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314(1):1–6.PubMedCrossRef
3.
Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries. J Am Coll Cardiol. 2011;57(17):1778–83.PubMedCrossRef
4.
Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291(15):1841–9.PubMedCrossRef
5.
Weisz G, Leon MB, Holmes DR, et al. Five-year follow-up after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2009;53(17):1488–97.PubMedCrossRef
6.
Alfonso F, Perez-Vizcayno M-J, Hernandez R, et al. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv. 2008;72(4):459–67.PubMedCrossRef
7.
Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation. 1995;91(9):2335–44.PubMedCrossRef
8.
Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation. 2005;111(25):3435–42.PubMedCrossRef
9.
•• Leacche M, Byrne J, Solenkova N, Reagan B, et al. Comparison of 30-day outcomes of coronary artery bypass grafting surgery verus hybrid coronary revascularization stratified by SYNTAX and euroSCORE. J Thorac Cardiovasc Surg. 2012;1–10. This study identifies patient populations best suited for hybrid therapy using SYNTAX and euroSCORE.
10.
Bachinsky WB, Abdelsalam M, Boga G, Kiljanek L, Mumtaz M, McCarty C. Comparative study of same sitting hybrid coronary artery revascularization versus off-pump coronary artery bypass in multivessel coronary artery disease. J Interv Cardiol. 2012;25(5):460–8. doi:10.​1111/​j.​1540-8183.​2012.​00752.​x.PubMedCrossRef
11.
Rab ST, Douglas Jr JS, Lyons E, et al. Hybrid coronary revascularization for the treatment of left main coronary stenosis: a feasibility study. Cathet Cardiovasc Interv. 2011;80(2):238–44.CrossRef
12.
Fedakar A, Tasar M, Rabus MB, Alsalehi S, Toker ME, Balkanay M. Hybrid coronary revascularization for the treatment of left main coronary artery disease in high-risk patients. Heart Surg Forum. 2012;15(1):E51–5.PubMedCrossRef
13.
• Halkos ME, Vassiliades TA, Douglas JS, et al. Hybrid coronary revascularization versus off-pump coronary artery bypass grafting for the treatment of multivessel coronary artery disease. Ann Thorac Surg. 2011;92(5):1695–702. This is the largest published series to date, concluding that Hybrid therapy is safe and effective in appropriately selected patients.PubMedCrossRef
14.
Hu S-S, Xiong H, Zheng Z, et al. Midterm outcomes of simultaneous hybrid coronary artery revascularization for left main coronary artery disease. Heart Surg Forum. 2012;15(1):E18–22.PubMedCrossRef
15.
The BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49(15):1600–1606.
16.
Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.PubMedCrossRef
17.
Willerson JT. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. Circulation. 1996;94(6):1194.PubMedCrossRef
18.
The BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) investigators. N Engl J Med. 1996;335(4):217–225.
19.
Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294(19):2446–54.PubMedCrossRef
20.
Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol. 2003;41(8):1293–304.PubMedCrossRef
21.
Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005;130(2):512–9.PubMedCrossRef
22.
Yan TD, Padang R, Poh C, et al. Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: a meta-analysis of randomized and nonrandomized studies. J Thorac Cardiovasc Surg. 2011;141(5):1134–44.PubMedCrossRef
23.
Zhao DX, Leacche M, Balaguer JM, et al. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization. J Am Coll Cardiol. 2009;53(3):232–41.PubMedCrossRef
24.
Us MH, Basaran M, Yilmaz M, et al. Hybrid coronary revascularization in high-risk patients. Tex Heart Inst J. 2006;33(4):458–62.PubMed
25.
Umakanthan R, Leacche M, Zhao DX, Gallion AH, Mishra PC, Byrne JG. Hybrid options for treating cardiac disease. Semin Thorac Cardiovasc Surg. 2011;23(4):274–80.PubMedCrossRef
26.
Lee M-S, Faxon DP. Revascularization of left main coronary artery disease. Cardiol Rev. 2011;19(4):177–83.PubMedCrossRef
27.
Balaguer JM, Umakanthan R, Leacche M, Byrne JG. Minimally invasive cardiac surgery. Curr Probl Surg. 2012;49(9):529–49.PubMedCrossRef
28.
Narasimhan S, Srinivas VS, DeRose Jr JJ. Hybrid coronary revascularization. Cardiol Rev. 2011;19(3):101–7.PubMedCrossRef
29.
de Canniere D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, Stoupel E. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: two-year follow-up of a new hybrid procedure compared with “on-pump” double bypass grafting. Am Heart J. 2001;142(4):563–70.PubMedCrossRef
30.
Bonatti J, Lehr EJ, Vesely M, et al. Hybrid coronary revascularization – techniques and outcome. Eur Surg. 2011;43(4):198–204.CrossRef
31.
Lloyd CT, Calafiore AM, Wilde P, et al. Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization. Ann Thorac Surg. 1999;68(3):908–11. discussion 911–2.PubMedCrossRef
32.
Lewis BS, Porat E, Halon DA, et al. Same-day combined coronary angioplasty and minimally invasive coronary surgery. Am J Cardiol. 1999;84(10):1246–7. A8.PubMedCrossRef
33.
Zenati M, Cohen HA, Griffith BP. Alternative approach to multivessel coronary disease with integrated coronary revascularization. J Thorac Cardiovasc Sur. 1999;117(3):439–44. discussion 444–6.CrossRef
34.
Wittwer T, Cremer J, Klima U, Wahlers T, Haverich A. Myocardial “hybrid” revascularization: intermediate results of an alternative approach to multivessel coronary artery disease. J Thorac Cardiovasc Sur. 1999;118(4):766–7.CrossRef
35.
Isomura T, Suma H, Horii T, Sato T, Kobashi T, Kanemitsu H. Minimally invasive coronary artery revascularization: off-pump bypass grafting and the hybrid procedure. Ann Thorac Surg. 2000;70(6):2017–22.PubMedCrossRef
36.
Presbitero P, Nicolini F, Maiello L, et al. “Hybrid” percutaneous and surgical coronary revascularization: selection criteria from a single-center experience. Ital Heart J. 2001;2(5):363–8.PubMed
37.
Cisowski M, Morawski W, Drzewiecki J, et al. Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization. Eur J Cardiothorac Surg. 2002;22(2):261–5.PubMedCrossRef
38.
Stahl KD, Boyd WD, Vassiliades TA, Karamanoukian HL. Hybrid robotic coronary artery surgery and angioplasty in multivessel coronary artery disease. Ann Thorac Surg. 2002;74(4):S1358–62.PubMedCrossRef
39.
Riess F-C, Bader R, Kremer P, et al. Coronary hybrid revascularization from January 1997 to January 2001: a clinical follow-up. Ann Thorac Surg. 2002;73(6):1849–55.PubMedCrossRef
40.
Lee MS, Wilentz JR, Makkar RR, et al. Hybrid revascularization using percutaneous coronary intervention and robotically assisted minimally invasive direct coronary artery bypass surgery. J Invasive Cardiol. 2004;16(8):419–25.PubMed
41.
Davidavicius G, Van Praet F, Mansour S, et al. Hybrid revascularization strategy: a pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention. Circulation. 2005;112(9 Suppl):I317–22.PubMed
42.
Kiaii B, McClure RS, Kostuk WJ, et al. Concurrent robotic hybrid revascularization using an enhanced operative suite. Chest. 2005;128(6):4046–8.PubMedCrossRef
43.
Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32(17):2125–34.PubMedCrossRef
44.
Katz MR, Van Praet F, de Canniere D, et al. Integrated coronary revascularization: percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass. Circulation. 2006;114(1 Suppl):I473–6.PubMed
45.
Vassiliades TAJ, Douglas JS, Morris DC, et al. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. J Thorac Cardiovasc Surg. 2006;131(5):956–62.PubMedCrossRef
46.
Gilard M, Bezon E, Cornily JC, et al. Same-day combined percutaneous coronary intervention and coronary artery surgery. Cardiology. 2007;108(4):363–7.PubMedCrossRef
47.
Kon ZN, Brown EN, Tran R, et al. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass. J Thorac Cardiovasc Surg. 2008;135(2):367–75.PubMedCrossRef
48.
Bonatti J, Schachner T, Bonaros N, et al. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of rapamycin eluting stents in the same interventional session. The COMBINATION pilot study. Cardiology. 2008;110(2):92–5.PubMedCrossRef
49.
Reicher B, Poston RS, Mehra MR, et al. Simultaneous “hybrid” percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes. Am Heart J. 2008;155(4):661–7.PubMedCrossRef
50.
Holzhey DM, Jacobs S, Mochalski M, et al. Minimally invasive hybrid coronary artery revascularization. Ann Thorac Surg. 2008;86(6):1856–60.PubMedCrossRef
51.
Hu S, Li Q, Gao P, et al. Simultaneous hybrid revascularization versus off-pump coronary artery bypass for multivessel coronary artery disease. Ann Thorac Surg. 2011;91(2):432–8.PubMedCrossRef
Metadaten
Titel
Combining PCI and CABG: the Role of Hybrid Revascularization
verfasst von
Kelly D. Green
Donald R. Lynch Jr.
Tyffany P. Chen
David Zhao
Publikationsdatum
01.04.2013
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 4/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-013-0351-9

Weitere Artikel der Ausgabe 4/2013

Current Cardiology Reports 4/2013 Zur Ausgabe

Interventional Cardiology (S Rao, Section Editor)

Identification and Management of Complications of Transradial Procedures

Valvular Heart Disease (V Nkomo, Section Editor)

Transcatheter Aortic Valve Replacement: Current Application and Future Directions

Peripheral Vascular Disease (M Shishehbor, Section Editor)

Management of Acute Ischemic Stroke

Nuclear Cardiology (V Dilsizian, Section Editor)

18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis

Ischemic Heart Disease (D Mukherjee, Section Editor)

HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?

Peripheral Vascular Disease (M Shishehbor, Section Editor)

Functional Impairment in Peripheral Artery Disease and How to Improve It in 2013

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise